Study of AMG 256 in Adult Subjects With Advanced Solid Tumors

NCT ID: NCT04362748

Last Updated: 2025-10-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 34 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-15
• Study Completion Date: 2023-09-21

Brief Summary

To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

Conditions

Advanced Solid Tumors

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Dose Escalation Phase

Determine the maximum tolerated dose (MTD) or the recommended phase 2 dose RP2D of AMG 256.

Group Type: EXPERIMENTAL

AMG 256

Intervention Type: DRUG

AMG 256 administered as an intravenous (IV) infusion.

Dose Expansion Phase: Group 1

Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.

Group Type: EXPERIMENTAL

AMG 256

Intervention Type: DRUG

AMG 256 administered as an intravenous (IV) infusion.

Dose Expansion Phase: Group 2

Participants will be administered with the MTD or RP2D of AMG 256 identified in the dose escalation part of the study.

Group Type: EXPERIMENTAL

AMG 256

Intervention Type: DRUG

AMG 256 administered as an intravenous (IV) infusion.

Interventions

AMG 256

AMG 256 administered as an intravenous (IV) infusion.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant has provided informed consent prior to initiation of any study specific activities/procedures.
• Age ≥ 18 years at the time of signing informed consent.
• Life expectancy of > 3 months, in the opinion of the investigator.
• Participant must have histologically or cytologically proven metastatic or locally advanced solid tumors not amenable to curative treatment with surgery or radiation for which:
• No standard therapy exists, or
• Standard therapy has failed, not available, or
• In the investigator's opinion, standard therapy does not result in meaningful clinical benefit.
• At least 1 measurable lesion ≥ 10 mm which has not undergone biopsy within 3 months of screening scan. This lesion cannot be biopsied at any time during the study.

Exclusion Criteria

• Primary brain tumor, untreated or symptomatic brain metastases and leptomeningeal disease.
• History of other malignancy within the past 2 years, with the following Exceptions:
• Malignancy treated with curative intent and with no known active disease present for ≥ 2 years before enrollment and felt to be at low risk for recurrence by the treating physician.
• Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
• Adequately treated cervical carcinoma in situ without evidence of disease.
• Adequately treated breast ductal carcinoma in situ without evidence of disease.
• Prostatic intraepithelial neoplasia without evidence of prostate cancer.
• Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ.
• History of solid organ transplantation.
• Major surgery within 28 days of study day 1.
• Live vaccine therapy within 4 weeks prior to study day 1.
• Currently receiving treatment in another investigational device or drug study, or less than 28 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
• Active infection requiring oral or intravenous therapy.
• Myocardial infarction within 6 months of study day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or cardiac arrhythmia requiring medication.
• History of severe allergic reactions or severe acute hypersensitivity reaction.
• Female participant is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 3 months after the last dose of AMG 256.
• Female participants of childbearing potential unwilling to use 1 highly effective method of contraception during treatment and for an additional 3 months after the last dose of AMG 256.
• Female participants of childbearing potential with a positive pregnancy test assessed within 48 hours prior to day 1 of treatment by a serum pregnancy test.
• Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 5 months after the last dose of AMG 256.
• Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 5 months after the last dose of AMG 256.
• Male participants unwilling to abstain from donating sperm during treatment and for an additional 5 months after the last dose of AMG 256.
• Participant has known sensitivity to any of the products or components to be administered during dosing.
• Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
• History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participants safety or interfere with the study evaluation, procedures or completion.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

MD

Role: STUDY_DIRECTOR

Amgen

Locations

City of Hope National Medical Center

Duarte, California, United States

Indiana University

Indianapolis, Indiana, United States

Washington University

St Louis, Missouri, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Chris OBrien Lifehouse

Camperdown, New South Wales, Australia

St Vincents Hospital Sydney

Darlinghurst, New South Wales, Australia

Monash Medical Centre

Clayton, Victoria, Australia

Cliniques Universitaires Saint Luc

Brussels, , Belgium

Universitair Ziekenhuis Gent

Ghent, , Belgium

Hospital Universitari Vall d Hebron

Barcelona, Catalonia, Spain

Hospital Clinic i Provincial de Barcelona

Barcelona, Catalonia, Spain

Countries

United States; Australia; Belgium; Spain

References

Kroenke MA, Starcevic Manning M, Zuch de Zafra CL, Zhang X, Cook KD, Archer M, Lolkema MP, Wang J, Hoofring S, Saini G, Aeffner F, Ahern E, Cabanas EG, Govindan R, Hui M, Gupta S, Mytych DT. Translatability of findings from cynomolgus monkey to human suggests a mechanistic role for IL-21 in promoting immunogenicity to an anti-PD-1/IL-21 mutein fusion protein. Front Immunol. 2024 Jan 26;15:1345473. doi: 10.3389/fimmu.2024.1345473. eCollection 2024.

Reference Type: BACKGROUND

PMID: 38343535 (View on PubMed)

Related Links

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

20180144

Identifier Type: -

Identifier Source: org_study_id